FDA says Ozempic shortage is over, chilling boom in off-brand versions
The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the end to the booming market for cheaper versions made by pharmacies.
Ozempic and Wegovy officially moved off FDA’s drug shortage list
Ozempic and Wegovy, the widely popular forms of semaglutide sold to treat diabetes and obesity, have officially been removed from the Food and Drug Administration’s (FDA) drug shortage list
Ozempic and Wegovy are no longer in shortage, FDA says
Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration said on Friday.
FDA declares end to Wegovy and Ozempic shortage
The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.
The Ozempic shortage is over
In this photo illustration, boxes of the diabetes drug Ozempic rest on a pharmacy counter on April 17, 2023 in Los Angeles, California. The shortage of Novo Nordisk’s (NVO) blockbuster diabetes and weight-loss drugs is officially over,
Generic Wegovy, Ozempic compounds may become harder to get as FDA removes drug from shortage list
Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug is no longer on the FDA shortage list.
Ozempic, Wegovy shortages are resolved in the U.S.: FDA
The drugmaker Novo Nordisk can meet present and future demand in the U.S. for its drugs including Ozempic and Wegovy, the U.S. Food and Drug Administration said.
Novo’s Ozempic, Wegovy Shortage Ends, Threatening Copycats
Novo Nordisk A/S’s weight-loss and diabetes drugs are no longer in short supply, US regulators said, a decision that’s expected to curtail widespread access to cheaper copies of the popular medications.
Shortage of popular drugs Wegovy and Ozempic is over, FDA says.
The FDA said the shortage of Novo Nordisk's weight-loss drugs Wegovy and Ozempic is resolved. The move could limit cheaper compounded versions
Ozempic and Wegovy shortage ends, setting up weight loss drug showdown
Ozempic and Wegovy, the popular GLP-1 drugs for diabetes and weight loss, are no longer in short supply, the FDA declared Friday. Why it matters: That's good news for Novo Nordisk (whose stock rose 5% Friday) and potentially bad news for Hims & Hers (which fell 26%).
Yearslong shortage of popular weight-loss and diabetes drugs is resolved, FDA says
Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of the popular diabetes and obesity treatments continue to improve, federal regulators said Friday.
Daily Express US on MSN9d
Ozempic and Zepbound linked to rare eye conditions that could cause blindness
A new study suggests popular weight-loss drugs like Ozempic and Zepbound may be linked to rare eye conditions that could ...
Some Ozempic users are developing serious eye issues that lead to blindness
A new study adds to a growing body of research suggesting a potential link between popular GLP-1 medications like Ozempic and ...
The Physicians Really Are Healing Themselves, With Ozempic
There are no studies documenting the percentage of doctors taking the drugs. But physicians “are a good litmus test for drugs ...
Ozempic shown to reduce drinking in first trial in alcohol-use disorder
For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...